Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Shimazaki, Ryutaro, Shiramoto, Masanari, Fukagawa, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514161/
https://www.ncbi.nlm.nih.gov/pubmed/30632107
http://dx.doi.org/10.1007/s40261-018-0737-y
_version_ 1783417839553609728
author Akizawa, Tadao
Shimazaki, Ryutaro
Shiramoto, Masanari
Fukagawa, Masafumi
author_facet Akizawa, Tadao
Shimazaki, Ryutaro
Shiramoto, Masanari
Fukagawa, Masafumi
author_sort Akizawa, Tadao
collection PubMed
description
format Online
Article
Text
id pubmed-6514161
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-65141612019-05-28 Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study” Akizawa, Tadao Shimazaki, Ryutaro Shiramoto, Masanari Fukagawa, Masafumi Clin Drug Investig Letter to the Editor Springer International Publishing 2019-01-10 2019 /pmc/articles/PMC6514161/ /pubmed/30632107 http://dx.doi.org/10.1007/s40261-018-0737-y Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Akizawa, Tadao
Shimazaki, Ryutaro
Shiramoto, Masanari
Fukagawa, Masafumi
Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
title Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
title_full Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
title_fullStr Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
title_full_unstemmed Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
title_short Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
title_sort response to comments on “pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy japanese subjects: first-in-human phase i study”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514161/
https://www.ncbi.nlm.nih.gov/pubmed/30632107
http://dx.doi.org/10.1007/s40261-018-0737-y
work_keys_str_mv AT akizawatadao responsetocommentsonpharmacokineticspharmacodynamicsandsafetyofthenovelcalcimimeticagentevocalcetinhealthyjapanesesubjectsfirstinhumanphaseistudy
AT shimazakiryutaro responsetocommentsonpharmacokineticspharmacodynamicsandsafetyofthenovelcalcimimeticagentevocalcetinhealthyjapanesesubjectsfirstinhumanphaseistudy
AT shiramotomasanari responsetocommentsonpharmacokineticspharmacodynamicsandsafetyofthenovelcalcimimeticagentevocalcetinhealthyjapanesesubjectsfirstinhumanphaseistudy
AT fukagawamasafumi responsetocommentsonpharmacokineticspharmacodynamicsandsafetyofthenovelcalcimimeticagentevocalcetinhealthyjapanesesubjectsfirstinhumanphaseistudy
AT responsetocommentsonpharmacokineticspharmacodynamicsandsafetyofthenovelcalcimimeticagentevocalcetinhealthyjapanesesubjectsfirstinhumanphaseistudy

Ejemplares similares